OSTEOPORE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.375 AUD | -6.25% |
|
+294.74% | -43.18% |
| 04-23 | Australian Shares Rise on Business Activity Growth; Osteopore Soars 127% | MT |
| 04-23 | Osteopore Commences In-Human Clinical Trials for Knee Preservation; Shares Surge 194% | MT |
| Sales 2022 | 1.69M 1.25M 1.9M 99.13M | Sales 2023 | 2.22M 1.63M 2.48M 130M | Capitalization | 6.82M 5.02M 7.64M 399M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -2.94M -4.48M -234M | Net income 2023 | -4M -2.94M -4.48M -234M | EV / Sales 2022 | 9.64 x |
| Net cash position 2022 | 1.27M 937K 1.43M 74.58M | Net cash position 2023 | 64.06K 47.13K 71.77K 3.75M | EV / Sales 2023 | 3.05 x |
| P/E ratio 2022 |
-4.42
x | P/E ratio 2023 |
-1.29
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.4% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.25% | ||
| 1 week | +294.74% | ||
| Current month | +25.00% | ||
| 1 month | +25.00% | ||
| 3 months | -26.47% | ||
| 6 months | -50.98% | ||
| Current year | -43.18% |
1 week
0.30
0.55
1 month
0.100.55
Current year
0.050.76
1 year
0.052.18
3 years
0.058.10
5 years
0.0522.35
10 years
0.0522.35
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Jing Lim
CEO | Chief Executive Officer | - | 30/11/14 |
Ning Voon Shu
AUD | Comptroller/Controller/Auditor | - | - |
Kellie Davis
SEC | Corporate Secretary | - | 25/01/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kei Wei Leong
CHM | Chairman | 49 | 31/07/21 |
Michael Keenan
BRD | Director/Board Member | - | 17/07/23 |
Swee Hin Teoh
BRD | Director/Board Member | - | 23/06/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.375 | -6.25% | 190 110 |
| 26/04/24 | 0.4 | +17.65% | 761,018 |
| 24/04/24 | 0.34 | -13.92% | 515,524 |
| 23/04/24 | 0.395 | +139.39% | 2,358,355 |
| 22/04/24 | 0.165 | +73.68% | 253,205 |
Delayed Quote Australian S.E., April 29, 2024 at 07:10 am
More quotes
Osteopore Limited is an Australia-based medical technology company. The Company is engaged in commercializing a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. The Companyâs patented technology fabricates specific micro-structured scaffolds for bone regeneration through three-dimensional (3D) printing and bioresorbable material. The Companyâs Osteoplug in plug and strip configuration fills craniotomy gaps effortlessly. It also promotes bone tissue integration, from the skull to the bone flap. Its craniofacial products include Osteomesh, Osteoplug, and Osteoplug-C. It also offers craniotomy, orbital floor reconstruction, socket preservation, cranioplasty patient-specific implants (PSI), craniosynostosis, guided bone regeneration, minimally invasive skull base surgery, endoscopic transsphenoidal skull base surgery, burr hole restoration with the shunt drainage system, mandible PSI, immediate implant loading, and more.
Calendar
29/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -43.18% | 2.69M | |
| -2.75% | 187B | |
| -2.06% | 106B | |
| -4.53% | 66.9B | |
| +0.60% | 49.45B | |
| +16.47% | 48B | |
| +4.06% | 40.84B | |
| +3.20% | 26.48B | |
| +0.68% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- OSX Stock
